Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Gnant, M; Singer, CF; Rinnerthaler, G; Pfeiler, G; Egle, D; Balic, M; Bartsch, R.
Position paper on CDK4/6 inhibitors in early breast cancer
MEMO-MAG EUR MED ONC. 2023;
Doi: 10.1007/s12254-023-00878-1
Web of Science
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Balic Marija
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Inhibitors of the cyclin-dependent kinases 4/6 (CDK4/6i) have been practice-changing and are now considered the standard of care in combination with endocrine therapy for the first- or second-line treatment in advanced hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Recently, CDK4/6i have also emerged as an appealing targeted cancer therapy in early breast cancer, however results of large clinical trials are controversial. This position paper summarizes the evidence, and provides guidance for clinical practice.
- Find related publications in this database (Keywords)
- Breast cancer
- Adjuvant therapy
- Cell cycle inhibitors
- CDK4
- 6 inhibitors